Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture oral polio vaccines (OPVs) in India for global supplies from drug substances manufactured in the Netherlands at BBio.
Hyderabad: Vaccine maker Bharat Biotech and Bilthoven Biologicals BV (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in the Netherlands, announced a collaboration.
A formal agreement has been inked between BBIL and BBio, wherein BBIL will procure drug substances for the production of oral polio vaccines to be distributed both within India and globally.